REVIEW

Low vitamin D serum levels as risk factor of Alzheimer's disease: a systematic review and meta-analysis

Rizaldy Taslim Pinzon[1,3], Theressia Handayani[1], Vincent Ongko Wijaya[2,3*] and Ranbebasa Bijak Buana[3]

Abstract

Past literatures have reported that changes in serum vitamin D levels are related to cognitive dysfunctions, such as dementia, including Alzheimer's disease (AD). However, these past studies vary in results on whether vitamin D levels correlated with the development of AD. This meta-analysis aimed to assess the associations between low vitamin D serum levels as risk factor of AD based on the latest evidence. We systematically searched Pubmed and additional references for relevant articles according to PRISMA guidelines from the beginning up to December 2022. The risk estimate of AD was determined using a pooled hazard ratio (HR) with 95% confidence intervals (CIs). five prospective trials and one cross-sectional study were analyzed. The meta-analysis showed that patients with low vitamin D serum levels (< 25 ng/ml) had an increased risk of developing AD compared to patients with normal vitamin D levels (≥ 25 ng/ml) (HR: 1.59, 95% CI: 1.09, 2.33, $I^2=77\%$). Further research is required to provide evidence on whether maintaining sufficient vitamin D serum levels may lower the risk of AD.

Keywords Alzheimer's disease, Deficiency, Vitamin D

Introduction

Dementia is a term to describe a clinical syndrome of acquired, progressive decline in cognitive functions in the loss of one or more cognitive abilities caused by brain disease or injury, severe enough to reduce a person's ability to perform daily activities [1]. Alzheimer's disease is a subtype of dementia, characterized by the formation of neuritic plaques and neurofibrillary tangles. The extracellular deposition of Aβ peptide, known as amyloid plaques. The neurofibrillary tangle consists of abnormal intracellular accumulations of phosphorylated tau protein within the perikaryal cytoplasm of certain neurons [2]. AD is the most common type of dementia, accounting for at least 75% of dementia cases in the elderly population. Approximately, there are around 50 million AD patients in the world and expected to increase by threefold in 2050 [2]. AD puts a heavy burden on healthcare systems around the world, costing more than $80 billion each year [3].

A past study by Perez-Lopez and colleagues reported the crucial role of vitamin D in maintaining cognitive function [4] another study also suggests the vitamin D receptors present in the brain regions responsible for cognitive functions and memory development [5]. The roles of Vitamin D in neurotrophy, neurotransmission, neuroprotection, and neuroplasticity may explain vitamin D deficiency involvement in the progression of AD [6]. Several past studies have reported the relationship between vitamin D deficiency and cognitive decline. An updated meta-analysis by Chai and colleagues reported significant associations between vitamin D deficiency and AD, with severe vitamin D deficiency having the strongest association [7] other meta-analyses also reported that Plasma or serum 25-hydroxyvitamin D concentration

*Correspondence:
Vincent Ongko Wijaya
vincent_wijaya007@yahoo.com
[1] Bethesda Hospital, Yogyakarta, Indonesia
[2] Panti Nugroho Hospital, Yogyakarta, Indonesia
[3] Duta Wacana Christian University, Yogyakarta, Indonesia

Pinzon *et al. Egypt J Neurol Psychiatry Neurosurg*   (2023) 59:88

Page 2 of 6

related to the risk of AD in inverse association [8]. The meta-analysis of the prospective cohort studies of Vitamin D concentration and the risk of AD reported that serum vitamin D deficiency or insufficiency was not statistically significant and associated with the risk of AD ([9]); this finding showed the inconsistent result between past meta-analysis. Thus, we are conducting an updated meta-analysis of vitamin D and AD association.

Methods

This study followed the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines [10].

Literature searching and selection method

Initially, two authors independently filtered the databases of the selected studies on PubMed up to December 2022, using specific keywords: "vitamin D" AND "Alzheimer." We used the following inclusion criteria to select eligible studies that assess the relationship between low vitamin D serum levels and Alzheimer's disease: (1) Observational studies that evaluated the association between low vitamin D serum levels at baseline and subjects with AD; (2) studies that reported hazard ratio (HR) alongside 95% confidence intervals (CIs) as risk estimates. The literature search was particularly for English language studies only. We excluded the following studies: (i) non-original articles (narratives, systematic review, meta-analyses, abstracts, comments, or editorials); (ii) case report/series; (iii) studies assessing other conditions not within our scope; (iv) incomplete data. The main outcome was the risk estimates of low vitamin D serum levels as risk factor of developing AD.

Data extraction and quality assessment

two independent authors read and inspected the titles and abstract according to the inclusion criteria—next, these authors examined a full-text review. If there were a lack of agreement between the two authors, the primary author would settle the disagreement and make a final judgment. Articles that matched the inclusion criteria were selected, and additional studies were retrieved according to the references of the articles collected.

We collected and summarized the subsequent data: Main author(s), publication years, study design, nation of origin, serum 25(OH)D levels, follow-up duration, and statistical adjustment. The Oxford Center for Evidence-Based Medicine (OCEBM) scale assessed each study's ratings. The scale categorized each study with ratings ranging from 1 to 5, with 1 meaning high-quality studies such as clinical trials and 5 representing case series/reports [11].

Statistical analysis

We conducted the analyses using Review Manager (RevMan) statistic software (version 5.3). The hazard ratio (HR) and 95% confidence interval (CI) were analyzed as effect size. We also analyzed I^2 statistics to assess heterogeneity between studies. I^2 of more than 50% was considered high heterogeneity. A Fixed-effects model was performed when there was no heterogeneity between studies. On the contrary, A random effects model will be used when data are considered heterogeneous. *P*-values of less than 0.05 ($P \leq 0.05$) were statistically significant [12, 13].

Results

Study characteristics

The initial search strategy identified 562 articles. After removing copies, followed by abstract screening, 24 full-text articles were evaluated for their eligibility. The final review included six articles [14–19] of five prospective studies and one cross-sectional. Figure 1. displays the PRISMA flow chart.

This process resulted in the selection of 6 studies that evaluated the relationship between vitamin D deficiency and AD, involving 10,884 participants for the meta-analysis. Of the included studies, author(s), publication years, study design, nation of origin, serum 25(OH)D levels, follow-up duration, statistical adjustment, and study ratings. Overall, most of the studies had high-quality ratings (Table 1). All selected studies observed patients with low vitamin D serum levels (< 25 ng/ml) as a risk factor of AD.

Low vitamin D serum levels and risk of AD

A meta-analysis with random effects model was conducted to summarize the estimated risk of AD in patients with low levels of serum vitamin D. The analysis showed that patients with low levels of vitamin D (< 25 ng/ml) had a greater risk of developing AD compared with those who had normal serum vitamin D levels (HR: 1.59, 95% CI: 1.09, 2.33, $I^2 = 77\%$, Fig. 2). The I^2 value was 77% indicating heterogeneity between studies.

Discussion

This meta-analysis provided additional evidence of low vitamin D levels and the risk of Alzheimer's disease. A total of 6 studies were included in this study, involving 10,884 participants. The analysis showed that patients with vitamin D deficiency (< 25 ng/ml) had a higher risk of AD compared to patients with adequate vitamin D supply (≥ 25 ng/ml). A previous meta-analysis [8] in 2018 reported the inverse association between 25-hydroxyvitamin D concentration to the risk of dementia. This study

Fig. 1 PRISMA flow chart of study selection

included Ten cohort studies with more than 20.000 participants. A year later, a meta-analysis involving twelve prospective cohort studies and four cross-sectional studies reported the same results as the previous meta-analysis. This meta-analysis reported a significant association between Vitamin D deficiency and dementia, with severe deficiency (< 10 ng/ml) having the strongest association compared to moderate vitamin D deficiency (10–20 ng/ml). [7] within the same year, other meta-analyses reported different results. Meta-analyses by Yang K and colleagues reported that the relation between vitamin D deficiency and insufficiency with the risk of AD was not statistically significant. This study involved six prospective cohort studies with more than 1000 AD cases [9].

The pathomechanism of AD may cause by two types of neuropathology changes. The first neuropathology change is a positive lesion due to the accumulation of neurofibrillary tangles, amyloid plaques, and other deposits in the AD patient's brain. The second neuropathology change is due to the loss of neuropil, neural and synaptic. Besides, neurodegeneration can cause by factors such as oxidative stress and neuroinflammation [2].

Several studies have reported vitamin D's potential benefit and relationship with AD. Vitamin D may affect

Pinzon *et al. Egypt J Neurol Psychiatry Neurosurg*   (2023) 59:88

Page 4 of 6

Table 1 Baseline characteristics of patients in the included studies

Authors	Study type	Nation of origin	No. of participants, (n)	Age, median (IQR, y) or Mean ± SD	Serum 25-hidroxyvitamin D [25(OH)D] levels, ng/mL	Follow-up duration (year)	Study quality level	Adjustment
Afzal et al. 2014 [14]	Prospective Cohort	Denmark	352	58	≤25 ng/mL	21	2	age, sex, month of blood sample, smoking status, body mass index, leisure time, work-related physical activity, alcohol consumption, income level, education, baseline diabetes mellitus, hypertension, cholesterol, HDL cholesterol, and creatinine
Littlejohns et al. 2014 [15]	Prospective Cohort	United States	1658	73.6 (4.5)	≤25 ng/mL	5.6	3	Age, season of vitamin D collection, education, sex, BMI, smoking, alcohol consumption, and depressive symptoms
Karakis et al. 2016 [16]	Prospective Cohort	United States	1663	72.4	<10 ng/mL	9	3	Age, gender, vascular risk factors (smoking, hypertension, diabetes, prevalent cardiovascular disease, and homocysteine), BMI, and vitamin D supplement use
Feart et al. 2017 [17]	Prospective Cohort	France	916	73.3	≤25 ng/mL	12	2	Gender, education, income, depressive symptomatology, number of drugs per day, apolipoprotein E ε4 allele, BMI, practice of physical exercise, diabetes, history of cardiovascular diseases and stroke, hypertension, hypercholesterolemia, hypertriglyceridemia, smoking status, and Mediterranean diet score
Licher et al. 2017 [18]	Prospective Cohort	Netherlands	6087	82.5 ± 8.6	≤25 ng/mL	13.3	2	Age, sex, season of blood collection, BMI, blood pressure, educational level, smoking, alcohol use, calcium serum levels, ethnicity, eGFR, TC, HDL, history of diabetes, heart failure, stroke, myocardial infarction, depressive symptoms, outdoor activity, and APOE-4 carrier status
Aguilar-Navarro et al. 2019 [19]	Cross sectional	Mexico	208	79 ± 1	≤20 ng/mL	NR	3	Age, sex and years of education

APOE-4 Apolipoprotein E4

BMI Body mass index

eGFR estimated glomerular filtration rate

HDL high-density lipoprotein

IQR Interquartile range

SD standard deviation

TC Triglycerides

Pinzon *et al. Egypt J Neurol Psychiatry Neurosurg*   (2023) 59:88

Page 5 of 6

Fig. 2 Risk association between low vitamin D levels (25(OH)D < 25 ng/ml) and AD

the first neuropathology change by promoting the clearing of amyloid plaques, as reported in animal and human studies [20, 21]. Vitamin D also prevents cognitive dysfunction via its roles in neuroprotection, neurotrophy, neurotransmission, and neuroplasticity, although its mechanism is still unclear [6]. Vitamin D also showed the potential to prevent neuroinflammation by inhibiting the production of TNF-a and IL 6 in in-vitro studies [22].

This study has limitations. Firstly, this study included one cross-sectional study, thus increasing the possibility of bias. Secondly, our study focused mainly on the relationship between Alzheimer's disease risk and low vitamin D levels. It was unclear whether the vitamin D level had changed in further follow-up. Lastly, the patients involved in this study are mainly from Europe and America. Thus this study may not be applied to the world population.

Conclusion

This meta-analysis provided evidence of the relationship between low vitamin D levels with the risk of AD. The random effects model analysis showed that low vitamin D levels (< 25 ng/ml) are a risk factor for developing AD. Maintaining normal vitamin D levels may lower the risk of AD.

Abbreviations

AD	Alzheimer's disease
CI	Confidence interval
HR	Hazard ratio
I^2	Heterogeneity statistic
IL-6	Interleukin-6
PRISMA	Preferred reporting items for systematic reviews and meta-analyses
TNF-a	Tumor necrosis factor alpha

Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References

1. Arvanitakis Z, Shah RC, Bennett DA. Diagnosis and management of dementia: review. JAMA. 2019;322(16):1589–99. https://doi.org/10.1001/jama.2019.4782.
2. Breijyeh Z, Karaman R. Comprehensive review on Alzheimer's disease: causes and treatment. Molecules. 2020;25(24):5789. https://doi.org/10.3390/molecules25245789.
3. Kelley AS, McGarry K, Gorges R, Skinner JS. The burden of health care costs for patients with dementia in the last 5 years of life. Ann Intern Med. 2015;163(10):729–36. https://doi.org/10.7326/M15-0381.
4. Pérez-López FR, Chedraui P, Fernández-Alonso AM. Vitamin D and aging: beyond calcium and bone metabolism. Maturitas. 2011;69(1):27–36.
5. Annweiler C, Schott AM, Berrut G, Chauviré V, le Gall D, Inzitari M, et al. Vitamin D and ageing: neurological issues. Neuropsychobiology. 2010;62(3):139–50.
6. Anjum I, Jaffery SS, Fayyaz M, Samoo Z, Anjum S. The role of vitamin D in brain health: a mini literature review. Cureus. 2018. https://doi.org/10.7759/cureus.2960.
7. Chai B, Gao F, Wu R, Dong T, Gu C, Lin Q, et al. Vitamin D deficiency as a risk factor for dementia and Alzheimer's disease: an updated meta-analysis. BMC Neurol. 2019;19(1):284.
8. Chen H, Xue W, Li J, et al. 25-Hydroxyvitamin D levels and the risk of dementia and Alzheimer's disease: a dose-response meta-analysis. Front Aging Neurosci. 2018;10:368.
9. Yang K, Chen J, Li X, Zhou Y. Vitamin D concentration and risk of Alzheimer disease: a meta-analysis of prospective cohort studies. Medicine (Baltimore). 2019;98(35):e16804. https://doi.org/10.1097/MD.0000000000016804.
10. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration

Pinzon *et al. Egypt J Neurol Psychiatry Neurosurg*   (2023) 59:88

Page 6 of 6

and explanation. BMJ. 2015;350:g7647. https://doi.org/10.1136/bmj.g7647.

11. Howick J, Chalmers I, Glasziou P, Greenhalgh T, Heneghan C, Liberati A, et al. The 2011 Oxford CEBM levels of evidence. Oxford Centre for Evidence-Based Medicine; 2011.

12. Higgins JPT, Green S. Medians and interquartile ranges. In: Higgins JPT, Green S, editors. Co-chrane handbook for systematic reviews of interventions 5.1. Oxford: Cochrane Collaboration; 2011.

13. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. https://doi.org/10.1136/bmj.d5928.

14. Afzal S, Bojesen SE, Nordestgaard BG. Reduced 25-hydroxyvitamin D and risk of Alzheimer's disease and vascular dementia. Alzheimers Dement. 2014;10(3):296–302. https://doi.org/10.1016/j.jalz.2013.05.1765.

15. Littlejohns TJ, Henley WE, Lang IA, Annweiler C, Beauchet O, Chaves PH, et al. Vitamin D and the risk of dementia and Alzheimer disease. Neurology. 2014;83(10):920–8. https://doi.org/10.1212/WNL.0000000000000755.

16. Karakis I, Pase MP, Beiser A, Booth SL, Jacques PF, Rogers G, et al. Association of serum vitamin D with the risk of incident dementia and subclinical indices of brain aging: the Framingham Heart Study. J Alzheimers Dis. 2016;51(2):451–61. https://doi.org/10.3233/JAD-150991.

17. Feart C, Helmer C, Merle B, Herrmann FR, Annweiler C, Dartigues JF, et al. 2017 Associations of lower vitamin D concentrations with cognitive decline and long-term risk of dementia and Alzheimer's disease in older adults. Alzheimers Dement. 2017;13(11):1207–16. https://doi.org/10.1016/j.jalz.2017.03.003.

18. Licher S, de Bruijn RFAG, Wolters FJ, Zillikens MC, Ikram MA, Ikram MK. Vitamin D and the risk of dementia: the Rotterdam study. J Alzheimers Dis. 2017;60(3):989–97. https://doi.org/10.3233/JAD-170407.

19. Aguilar-Navarro SG, Mimenza-Alvarado AJ, Jiménez-Castillo GA, Bracho-Vela LA, Yeverino-Castro SG, Ávila-Funes JA. Association of vitamin D with mild cognitive impairment and alzheimer's dementia in older mexican adults. Rev Invest Clin. 2019;71(6):381–6. https://doi.org/10.24875/RIC.19003079.

20. Briones TL, Darwish H. Vitamin D mitigates age-related cognitive decline through the modulation of pro-inflammatory state and decrease in amyloid burden. J Neuroinflammation. 2012;9:244. https://doi.org/10.1186/1742-2094-9-244.

21. Masoumi A, Goldenson B, Ghirmai S, Avagyan H, Zaghi J, Abel K, et al. 2009 1alpha,25-dihydroxyvitamin D3 interacts with curcuminoids to stimulate amyloid-beta clearance by macrophages of Alzheimer's disease patients. J Alzheimers Dis. 2009;17(3):703–17. https://doi.org/10.3233/JAD-2009-1080.

22. Lefebvre d'Hellencourt C, Montero-Menei CN, Bernard R, Couez D. Vitamin D3 inhibits proinflammatory cytokines and nitric oxide production by the EOC13 microglial cell line. J Neurosci Res. 2003;71(4):575–82. https://doi.org/10.1002/jnr.10491.

Publisher's Note